Treatment of opportunistic mycoses: How long is long enough?

Lancet Infectious Diseases

Volumn 3, Issue 11, 2003, Pages 703-708

  Singh, Nina ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

CLINICAL TRIAL; DECISION MAKING; DRUG COST; DRUG USE; HUMAN; MYCELIUM; MYCOSIS; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION;

EID: 0242386559     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00802-8     Document Type: Review

References (40)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
2. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692-96.
3. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-72.
4. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
5. Beck-Sague CM, Jarvis WR, and the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 247-51.
6. Marr KA, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoeitic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
7. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-30.
8. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15.
9. Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin B colloidal dispersion. Chemotherapy 1999; 45: 67-76.
10. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amhotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
11. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001; 20: 77-82.
12. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155: 1093-98.
13. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754-60.
14. Jantunen E, Ruutu P, Piilonen A, Volin L, Parkkali T, Ruutu T. Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 26: 759-62.
15. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000; 79: 250-60.
16. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invsive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28: 73-82.
17. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
18. Denning D, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
19. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in paients with neutropenia. J Clin Oncol 2001; 19: 253-59.
20. Caillot D, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 32: 83-90.
21. Kretschmar M, Buhheidt D, Hol H, Nichterlein T. Galactomannan enzyme immunoassay for monitoring sytemic infection with Aspergillus fumigatus in mice. Mycology 2001; 41: 107-12.
22. Offner F, Cordonnier C, Liungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098-103.
23. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-18.
24. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7: 1-7.
25. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15-21.
26. Singh N, Alexander B, Gupta KL, and and the Cryptococcus Collaborative Transplant Group. Characteristics and outcome of Cryptococcus neoformans infection of the central nervous system in organ transplant recipients: a prospective, multicenter study. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September, 2002. Abstract M-885.
27. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 2000; 30: 47-54.
28. Lortholary O, Nicolas M, Soreda S, et al. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother 1999; 43: 817-24.
29. Pappas PA, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33: 690-99.
30. Rose HD. Venous catheter-associated candidemia. Am J Med Sci 1978; 275: 265-69.
31. Edwards JE, Bodey CP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
32. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
33. Anaissie E, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
34. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
35. Rex JH, Bennett JE, Sugar AM, et al. Randomized trial comparing fluconazole with amphotericin B for the treatment ofcandidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30.
36. Mora-Duarte J, Betts R, Rostein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-29.
37. Oude Lashof AML, Donnelly JP, Meis JFGM, Meer JWM, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003; 22: 43-48.
38. Fichtenbaum CJ, German M, Dunagan WC, et al. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis 1999; 29: 1551-56.
39. Singh N. Cytomegalovirus infection in liver transplant recipients: comparison of antigenemia and molecular biology assay. Liver Transplant 2001; 7: 1004-07.
40. Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998; 65: 1477-81.